Legend Capital has returned to invest in the metabolic and immunological disease-focused biotechnology developer, having backed its series A round two years ago.
China-based metabolic disease therapy developer Sciwind Biosciences has raised $37m in series B funding from investors including Legend Capital, the venture capital firm spun out of conglomerate Legend Holdings.
Life sciences-focused investment firm Lyfe Capital led the round, investing with VC firm Haibang Venture Capital, which was identified as an existing backer.
Founded in 2017, Sciwind is working on drugs targeting chronic metabolic and immunological disorders.
The company’s lead product candidate, XW003, is being developed to treat type 2 diabetes,…
